Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 14, 2020 16:05 ET | Source: NextCure

NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors

BELTSVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
September 08, 2020 08:05 ET | Source: NextCure

NextCure to Present at Morgan Stanley Virtual 18th Annual Global Healthcare Conference

BELTSVILLE, Md., Sept. 08, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
August 06, 2020 16:03 ET | Source: NextCure

NextCure Reports Second Quarter 2020 Financial Results

BELTSVILLE, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
August 05, 2020 08:05 ET | Source: NextCure

NextCure to Present at BTIG Virtual Biotechnology Conference

BELTSVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
July 13, 2020 06:05 ET | Source: NextCure

NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer

BELTSVILLE, Md., July 13, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
July 07, 2020 16:05 ET | Source: NextCure

NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors

BELTSVILLE, Md., July 07, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
May 29, 2020 08:05 ET | Source: NextCure

NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting

BELTSVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
May 07, 2020 17:10 ET | Source: NextCure

NextCure Reports First Quarter 2020 Financial Results

BELTSVILLE, Md., May 07, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
May 06, 2020 08:05 ET | Source: NextCure

NextCure to Present at BofA Securities Virtual Health Care Conference

BELTSVILLE, Md., May 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
April 13, 2020 07:05 ET | Source: NextCure

NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic

BELTSVILLE, Md., April 13, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...